| 발표일자: |
2016년 4월 9일(토) 10:00 ~ 4월 10일(일) |
| 발표번호: |
P(e-poster)-040 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| 망막혈관종성증식에 동반된 황반하 출혈 환자에서 유리체강내 항혈관내피세포성장인자 주입술 단독요법의 임상적 결과 |
| 건양대학교 의과대학 김안과병원 안과학교실 명곡안연구소 |
| 김경민, 김재휘, 장영석, 김종우, 김철구, 이태곤 |
|
목적 : To evaluate the outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy for the treatment of submacular hemorrhage secondary to retinal angiomatous proliferation (RAP).
방법 : This retrospective study included 21 eyes of 21 patients who had been diagnosed with submacular hemorrhage secondary to RAP. All patients had been treated with anti-VEGF monotherapy. The best-corrected visual acuity (BCVA), measured at the time of hemorrhage development, was compared with that measured after 6 months of treatment and at the final follow-up. Factors predictive of visual outcome were also identified.
결과 : The mean follow-up period was 20.5 ± 13.7 months after the development of hemorrhage. The mean BCVA values, measured at the time of hemorrhage development, at 6 months of treatment, and at the final follow-up were 1.21 ± 0.56, 1.35 ± 0.78, and 1.63 ± 0.84, respectively. The mean BCVA at 6 months was not significantly different from the baseline value (P = 0.645), whereas the mean BCVA at the final visit was significantly worse than the baseline value (P = 0.025). The BCVA at 6 months was significantly associated with the BCVA at the final visit (P< 0.001).
결론 : The treatment outcomes in submacular hemorrhage secondary to retinal angiomatous proliferation were generally unfavorable. BCVA at 6 months may be an indicator of long-term visual prognosis.
|
| |